An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary tumours
- Focus Therapeutic Use
- Acronyms Passion I; Passion-1
- Sponsors Novartis Pharmaceuticals
- 10 May 2018 Status changed from recruiting to completed.
- 30 Dec 2016 Planned End Date changed from 1 Dec 2014 to 1 Sep 2017.
- 30 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.